

References

I-140

1. Brunelli MJ, Atallah ÁN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. *Cochrane Database Syst Rev*. 2016(3):CD009806.
2. Galsulfase (Naglazyme) intravenous infusion [package insert] Novato. CA: *BioMarin*; 2005. Revised 12/2019.
3. US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Galsulfase (Naglazyme®) Product approval information, approval letter 125117, 05/2005.
4. Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up. *Mol Genet Metab Rep*. 2017;13: 69–75.
5. Clinical Pharmacology Compendia. 2020 Tampa FL: Gold Standard, Inc. Galsulfase.
6. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
7. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
8. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
9. Quartel A, Harmatz PR, Lampe C, et al. Long-term galsulfase treatment associated with improved survival of patients with mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) 15-year follow-up from the survey study. *J Inborn Errors Metab Screen*. 2018: 6:2326409818755800.
10. Akyol MU, Alden TD, Amartino H, et al. Recommendations for the management of MPS VI: systematic evidence-and consensus-based guidance. *Orphanet J Rare Dis*. 2019;1;14(1):118.